Crown Laboratories and Revance Therapeutics Announce Expiration of Tender Offer
1. Crown's tender offer for Revance expired on February 4, 2025. 2. 86.2% of shares were tendered, indicating strong shareholder support. 3. Acquisition expected to consummate on February 6, 2025. 4. Crown is a leader in dermatology and aesthetics. 5. Revance's innovative products could enhance market position post-acquisition.